Jaguar Health Executes Out-License Deal With Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia
Jaguar Health Executes Out-License Deal With Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia
The drug candidate demonstrates antipsychotic activity and has a mechanism of action distinct from FDA-approved therapies for schizophrenia and other mental conditions that present psychotic symptoms
該候選藥物具有抗精神病活性，其作用機制與美國食品藥品管理局批准的精神分裂症和其他出現精神病症狀的精神疾病療法截然不同
Jaguar to receive percent of milestone payments and increasing royalties upon commercialization into the U.S. schizophrenia market, which is estimated to reach $8.06 billion by 2030
捷豹在美國精神分裂症市場商業化後將獲得里程碑式付款的百分比並增加特許權使用費，預計到2030年該市場將達到80.6億美元
Jaguar to present May 30 at Lytham Partners Spring 2024 Investor Conference. Click here to register for conference.
捷豹將於5月30日亮相 Lytham Partners 2024 春季投資者會議。點擊 這裏 註冊參加會議。
SAN FRANCISCO, CA / ACCESSWIRE / May 29, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the company's out-licensing agreement with Magdalena Biosciences, Inc. ("Magdalena"), the joint venture formed by Jaguar and Filament Health Corp. (OTCQB:FLHLF)(CBOE CA:FH)(FSE:7QS) to develop novel, natural prescription medicines derived from plants for mental health indications, has been expanded to cover ethnobotanical know-how related to development of a prescription drug compound (the "Botanical Drug Candidate") from a specified medicinal plant for possible schizophrenia and psychoses indications and for development with potential corporate partners.
加利福尼亞州舊金山/ACCESSWIRE/2024年5月29日/捷豹健康公司（納斯達克股票代碼：JAGX）（“捷豹”）今天宣佈，該公司與捷豹和Filament Health Corp.（OTCQB: FLHLF）（CBOE CA: FH）（FSE: 7QS）組建的合資企業瑪格達萊納生物科學公司（“瑪格達萊納”）簽訂了外包許可協議開發源自植物的新型天然處方藥，用於心理健康適應症，現已擴展到涵蓋與開發特定藥用植物的處方藥化合物（“植物候選藥物”）相關的民族植物學專業知識研究可能的精神分裂症和精神病適應症，並與潛在的企業合作伙伴共同開發。
"We are very happy to have executed the out-licensing arrangement with Magdalena related to the Botanical Drug Candidate," said Lisa Conte, Jaguar's president and CEO. "The amended license agreement between Jaguar and Magdalena stipulates that Jaguar will receive 10% of all upfront payments, milestone payments, and similar payments received by Magdalena as part of any business development partnerships Magdalena enters for the Botanical Drug Candidate, excluding commercial milestones and R&D reimbursements, up to a defined cap amount. The amended license agreement also stipulates that Jaguar will receive royalties on annual net sales of the Botanical Drug Candidate by Magdalena and any sublicensees, if the Botanical Drug Candidate receives FDA approval and is commercialized, with the royalty percentage increasing if annual net sales surpass a defined dollar amount."
捷豹總裁兼首席執行官麗莎·孔戴錶示：“我們很高興與瑪格達萊納簽署了與植物候選藥物有關的外包許可協議。”“捷豹和瑪格達萊納之間修訂後的許可協議規定，捷豹將獲得瑪格達萊納收到的所有預付款、里程碑付款和類似款項的10％，這是瑪格達萊納爲植物候選藥物建立的任何業務發展合作伙伴關係的一部分，不包括商業里程碑和研發報銷，但不超過規定的上限。修訂後的許可協議還規定，如果植物候選藥物獲得美國食品藥品管理局的批准並實現商業化，捷豹將獲得瑪格達萊納和任何分許可人對該候選植物藥的年淨銷售額的特許權使用費，如果年度淨銷售額超過規定的美元金額，特許權使用費百分比將增加。”
The U.S. schizophrenia market is projected to grow to $8.06 billion by 2030, according to a market research report by Market Research Future.1
根據市場研究未來的一份市場研究報告，到2030年，美國精神分裂症市場預計將增長到80.6億美元。1
Neuropsychopharmacology profile analysis shows the Botanical Drug Candidate demonstrates antipsychotic activity and has a mechanism of action distinct from FDA-approved therapies for schizophrenia and other mental conditions that present psychotic symptoms. Magdalena, which is approximately 40-percent owned by Jaguar, is focused on advancing plant-based innovation for patients and on identifying the next generation of plant-based first-in-class agents for treatment of mental health conditions. The Botanical Drug Candidate has a long history of use by traditional healers and may have the potential to be the first in a new class of plant-based antipsychotic compounds.
神經心理藥理學特徵分析顯示，該候選植物藥具有抗精神病活性，其作用機制與美國食品藥品管理局批准的精神分裂症和其他出現精神病症狀的精神疾病療法截然不同。瑪格達萊納由捷豹持有約40％的股權，專注於爲患者推進植物基創新，並確定用於治療心理健康狀況的下一代植物基首創藥物。植物學候選藥物在傳統治療師中的使用歷史悠久，有可能成爲新一類植物基抗精神病藥物化合物中的第一種。
"Our team has always recognized and valued the unique and powerful knowledge Indigenous and traditional peoples have about plants, ecosystems, and healing compounds," said Steven King, Ph.D., Jaguar's chief sustainable supply and ethnobotanical research officer and an Advisor to Magdalena. "Jaguar's library of approximately 2,300 medicinal plants from tropical regions - developed over three decades by medicinal tropical scientific strategy team advisors, including ethnobotanists, physicians, pharmacologists, chemists, and experts in neuropharmacology from around the world - comprises a unique asset to drive drug discovery. The plant collection was assembled by teams of experts who conducted primary, first-hand field investigations and plant identification work in rainforest regions around the globe in addition to gathering data about traditional medicinal uses of plants from shamans and other Indigenous healers."
捷豹首席可持續供應和民族植物學研究官兼瑪格達萊納顧問史蒂芬·金博士說：“我們的團隊一直認可和重視土著和傳統人民對植物、生態系統和治療化合物的獨特而強大的知識。”“捷豹的約2300種來自熱帶地區的藥用植物庫是由藥用熱帶科學戰略團隊顧問（包括來自世界各地的民族植物學家、醫生、藥理學家、化學家和神經藥理學專家）在三十年中開發的，是推動藥物發現的獨特資產。植物藏品是由專家小組收集的，他們在全球雨林地區進行了初步的第一手實地調查和植物鑑定工作，此外還從薩滿和其他土著治療師那裏收集了有關植物傳統藥用途的數據。”
Schizophrenia, the most serious form of psychosis, is a chronic, disabling mental illness that affects approximately one percent of the U.S. population.2 It is estimated that up to 34% of patients with schizophrenia fail to respond to currently available treatments.3 Psychotic symptoms can also be present in other mental illnesses, including depression, bipolar disorder, dementia, and borderline personality disorder.
精神分裂症是最嚴重的精神病，是一種慢性致殘性精神疾病，影響着大約百分之一的美國人口。2 據估計，多達34％的精神分裂症患者對目前可用的治療沒有反應。3 精神病症狀也可能出現在其他精神疾病中，包括抑鬱症、躁鬱症、癡呆和邊緣性人格障礙。
Jaguar to Participate in Lytham Partners Spring 2024 Investor Conference on May 30th
捷豹將於5月30日參加萊瑟姆合夥人2024年春季投資者會議第四
Jaguar will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.
捷豹將在2024年5月30日星期四虛擬舉行的Lytham Partners2024年春季投資者大會上參加網絡直播的演講，並主持與投資者的一對一會議。
The webcasted presentation will take place at 2:00 pm Eastern on Thursday, May 30, 2024. The webcast can be accessed by visiting the conference home page at or directly at The webcast will also be available for replay following the event.
網絡直播的演講將於美國東部時間2024年5月30日星期四下午2點舉行。可以通過訪問會議主頁或直接訪問網絡直播。活動結束後，網絡直播也將可供重播。
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at
管理層將在整個活動期間參加虛擬的一對一會議。要安排與管理層的會面，請致電 1× 1@lythampartners.com 與 Lytham Partners 聯繫或通過以下地址註冊參加該活動
About Botanicals Drugs
關於植物藥物
Botanicals drugs are defined by the U.S. Food and Drug Administration (FDA) as "products from plant materials, algae, macroscopic fungi, and combinations thereof." Many botanical drugs have a long history of safe use in traditional medicines, which may be documented and reviewed in scientific literature. Existing scientific literature on safety may accelerate the safety review process for a botanical drug, reducing the scope and financial burden for extensive safety studies. The FDA has established guidance on botanical drug development and recognizes the complexity of botanical drugs. Additionally, botanicals drugs, by virtue of their complexity, have the added benefit of being difficult to genericize. Hence there are often multiple opportunities for creating 'trade-secrets,' as well as novel patents around a botanical drug substance, its processing, its formulation, and so forth.
美國食品藥品監督管理局（FDA）將植物藥定義爲 “來自植物材料、藻類、宏觀真菌及其組合物的產品”。許多植物藥物在傳統藥物中的安全使用歷史悠久，科學文獻中可能會記錄和審查這些藥物。關於安全性的現有科學文獻可能會加快植物藥物的安全性審查過程，從而縮小廣泛安全性研究的範圍和財務負擔。美國食品藥品管理局已經制定了植物藥物開發指導方針，並認識到植物藥物的複雜性。此外，植物藥物由於其複雜性，還有一個額外的好處，那就是難以仿製。因此，通常有多種機會創造 “商業祕密”，以及圍繞植物藥物物質、其加工、配方等獲得新專利。
ABOUT FILAMENT HEALTH (OTCQB:FLHLF)(CBOE CA:FH)(FSE:7QS)
關於燈絲健康（OTCQB: FLHLF）（CBOE CA: FH）（FSE: 7QS）
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.
Filament Health是一家臨床階段的天然迷幻藥物開發公司。我們相信，安全、標準化、天然衍生的迷幻藥物可以改善許多人的生活，我們的使命是儘快將它們送到每個需要它們的人手中。Filament 的專有知識產權平台允許發現、開發和交付用於臨床開發的天然迷幻藥物。我們正在爲有史以來第一種天然迷幻候選藥物鋪平道路。
Learn more at and on Twitter and LinkedIn.
在推特和領英上了解更多信息。
About the Jaguar Health Family of Companies
關於 Jaguar Health 旗下公司
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
Jaguar Health, Inc.（Jaguar）是一家商業階段的製藥公司，專注於開發可持續地從雨林地區植物中提取的新型專有處方藥，用於患有胃腸道不適的人和動物，特別與腸道過度活躍有關，包括慢性衰弱性腹瀉、尿急、腸失禁和抽筋痛等症狀。捷豹家族企業Napo Pharmaceuticals專注於開發和商業化人類處方藥，用於在多種複雜疾病狀態下提供基本支持性護理和管理被忽視的胃腸道症狀。Napo Pharmaceuticals的crofelemer候選藥物產品是OnTarget研究的主題，該研究是一項關鍵的3期臨床試驗，旨在通過靶向治療預防性治療成年癌症患者化療誘發的腸道過度活躍（CIOB）。捷豹家族企業Napo Therapeutics是一家意大利公司，捷豹於2021年在意大利米蘭成立，專注於擴大crofelemer在歐洲的使用範圍，特別是孤兒和/或罕見疾病。Jaguar Animal Health 是捷豹的商品名。瑪格達萊納生物科學是由捷豹和Filament Health Corp. 成立的合資企業，源自捷豹的Entheogen Therapeutics倡議（ETI），專注於開發源自植物的新型處方藥，用於心理健康適應症。
For more information about:
有關以下內容的更多信息：
Jaguar Health, visit
捷豹健康，訪問
Napo Pharmaceuticals, visit
納波製藥，參觀
Napo Therapeutics, visit napotherapeutics.com
Napo Therapeutics，訪問 napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
瑪格達萊納生物科學公司，訪問 magdalenabiosciences.com
Visit Jaguar on LinkedIn:
在 LinkedIn 上訪問捷豹：
Visit Jaguar on X:
在 X 上訪問捷豹：
Visit Jaguar on Instagram:
在 Instagram 上訪問捷豹：
Forward-Looking Statements
前瞻性陳述
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Jaguar will receive 10% of all upfront payments, milestone payments, and similar payments received by Magdalena as part of any business development partnerships Magdalena enters for the Botanical Drug Candidate, excluding commercial milestones and R&D reimbursements, up to a defined cap amount, the expectation that Jaguar will receive royalties on annual net sales of the Botanical Drug Candidate by Magdalena and any sublicensees if the Botanical Drug Candidate receives FDA approval and is commercialized, the expectation that the Botanical Drug Candidate may have the potential to be the first in a new class of plant-based antipsychotic compounds, and the expectation that Jaguar will participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
本新聞稿中的某些陳述構成 “前瞻性陳述”。其中包括以下聲明：預計捷豹將獲得瑪格達萊納爲植物學候選藥物建立的任何業務發展合作伙伴關係的一部分，瑪格達萊納收到的所有預付款、里程碑付款和類似款項的10％，不包括商業里程碑和研發報銷，但不超過規定的上限；預計捷豹將獲得瑪格達萊納和任何分許可人的植物候選藥物年度淨銷售額的特許權使用費獲得批准並已商業化，預計該植物候選藥物有可能成爲新一類植物基抗精神病藥物化合物中的第一種，並預計捷豹將於2024年5月30日參加Lytham Partners2024年春季投資者會議。在某些情況下，您可以通過諸如 “可能”、“將”、“應該”、“計劃”、“目標”、“預測”、“可能”、“打算”、“目標”、“項目”、“考慮”、“相信”、“估計”、“預測”、“潛在” 或 “繼續” 等術語來識別前瞻性陳述，或者這些術語或其他類似表述的否定詞。本新聞稿中的前瞻性陳述只是預測。捷豹的這些前瞻性陳述主要基於其當前對未來事件的預期和預測。這些前瞻性陳述僅代表截至本新聞稿發佈之日，受許多風險、不確定性和假設的影響，其中一些是無法預測或量化的，還有一些是捷豹無法控制的。除非適用法律要求，否則捷豹不計劃公開更新或修改此處包含的任何前瞻性陳述，無論是由於任何新信息、未來事件、情況變化還是其他原因。
1
1
2 Bromet EJ, Dew MA, Eaton W. Epidemiology of psychosis with special reference to schizophrenia. In: Tsuang MT, Tohen M, Zahner GEP, eds. Textbook in psychiatric epidemiology. New York: John Wiley, 1996:283-300
2 Bromet EJ、Dew MA、Eaton W. 精神病流行病學，特別提及精神分裂症。載於：Tsuang MT、Tohen M、Zahner GEP，編輯。精神流行病學教科書。紐約：約翰·威利，1996:283-300
3 Demjaha, A. et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol. Med 47, 1981-1989 (2017); Lally, J. et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol. Med 46, 3231-3240 (2016); Meltzer, H. Y. et al. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am. J. Psychiatry 154, 475-482 (1997).
3 Demjaha、A. 等人首次發作精神病的抗精神病藥物耐藥性：患病率、亞型和預測因素。Psychol。Med 47，1981-1989 (2017)；Lally, J. 等人兩種不同的耐藥模式：首發精神分裂症譜系精神病耐藥性的臨床預測指標。Psychol。Med 46，3231-3240（2016）；Meltzer、H.Y. 等人精神分裂症患者的發病年齡和性別與抗精神病藥物耐藥性的關係。上午。J.《精神病學》154、475-482（1997）。
Contact:
聯繫人：
hello@jaguar.health
Jaguar-JAGX
hello@jaguar.health
Jaguar-Jagx
SOURCE: Jaguar Health, Inc.
來源：捷豹健康公司
譯文內容由第三人軟體翻譯。